Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Wednesday, June 5, 2024 1 min read

Key Takeaway: Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Full Press Release Details

Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH).

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details